A protective effect of sulindac against
β
Dr. M. Moorghen; P. Ince; Karen J. Finney; J. P. Sunter; D. R. Appleton; A. J. W
π
Article
π
1988
π
John Wiley and Sons
π
English
β 558 KB
Sulindac, a non-steroidal anti-inflammatory drug, has been reported to lead to tumour regression in cases of human polyposis coli. We have investigated the effects of this drug on the growth of 1,2-dimethylhydrazine (DMH)-induced mouse colonic tumours. In one experiment, DMH and oral sulindac were a